(Q35883611)

10 August 2017

Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes (English)

1 reference

10 August 2017

Chou SY

1

1 reference

10 August 2017

Chou CK

series ordinal

2

1 reference

10 August 2017

Kuang TM

series ordinal

3

1 reference

10 August 2017

Hsu WM

series ordinal

4

1 reference

10 August 2017

1 July 2005

1 reference

10 August 2017

1 reference

10 August 2017

19

1 reference

10 August 2017

7

1 reference

10 August 2017

784-787

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.eye.6701663

10 August 2017

0 references

cites work

alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

Increased eyelid pigmentation associated with use of latanoprost

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

Prostaglandin analogs in the treatment of glaucoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.EYE.6701663

7 January 2021

Identifiers

DOI

10.1038/SJ.EYE.6701663

1 reference

10 August 2017

1 reference